Investigational New Drugs

, Volume 27, Issue 4, pp 389–390 | Cite as

Blackberry-induced hand-foot skin reaction to sunitinib

  • Susan L. Boone
  • Gayle Jameson
  • Daniel Von Hoff
  • Mario E. LacoutureEmail author


Sunitinib is an orally administered small molecule that was approved by the US Food and Drug Administration in January 2006 as monotherapy for the treatment of patients with advanced renal cell carcinoma (RCC) and patients with gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. Data pooled from multiple sunitinib dose-escalation trials showed that sunitinib is associated with various adverse events, with HFSR occurring in up to 20% of patients. We describe a 48-year-old woman with a history of metastatic colorectal cancer treated with single-agent sunitinib who developed pain and tenderness in areas of friction secondary to Blackberry use, and was diagnosed with trauma-induced hand-foot skin reaction (HFSR) secondary to sunitinib therapy.


Hand-foot skin reaction Sunitinib 


  1. 1.
    Rock EP, Goodman V, Jiang JX et al (2007) Food and drug administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 12(1):107–113. doi: 10.1634/theoncologist.12-1-107 PubMedCrossRefGoogle Scholar
  2. 2.
    Tsai KY, Yang CH, Kuo TT et al (2006) Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma. J Clin Oncol 24(36):5786–5788. doi: 10.1200/JCO.2006.08.6868 PubMedCrossRefGoogle Scholar
  3. 3.
    Wilkes GM, Doyle D (2005) Palmar-plantar erythrodysesthesia. Clin J Oncol Nurs 9(1):103–106. doi: 10.1188/05.CJON.31-44 PubMedCrossRefGoogle Scholar
  4. 4.
    Eming SA, Krieg T (2006) Molecular mechanisms of VEGF-A action during tissue repair. J Investig Dermatol Symp Proc 11(1):79–86. doi: 10.1038/sj.jidsymp.5650016 PubMedCrossRefGoogle Scholar
  5. 5.
    Robert C, Faivre S, Raymond E et al (2005) Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors? Ann Intern Med 143(4):313–314PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Susan L. Boone
    • 1
  • Gayle Jameson
    • 2
  • Daniel Von Hoff
    • 2
  • Mario E. Lacouture
    • 1
    • 3
    Email author
  1. 1.Department of DermatologyNorthwestern University’s Feinberg School of MedicineChicagoUSA
  2. 2.Department of Medicine Arizona Cancer CenterTucsonUSA
  3. 3.SERIES Clinic, Robert H Lurie Comprehensive Cancer CenterNorthwestern UniversityChicagoUSA

Personalised recommendations